Bioventix PLC (BVXP)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

2,800.00p

Buy

2,900.00p

arrow-up0.00p (+0.00%)

Prices updated at 12 May 2025, 16:39 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Bioventix PLC is engaged in the field of biotechnology. Its business involves the development of high-affinity sheep monoclonal antibodies and clinical diagnostics and drugs of abuse testing.
FTSE All-Share
arrow-up0.6%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Ian James Nicholson
CEO
Mr. Peter John Harrison
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
17
Head office
27–28 Eastcastle Street
London
United Kingdom
W1W 8DH
mobile
-
letter
info@bioventix.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Ian James Nicholson
Non-Executive Director, Chairman
-
Mr. Nicholas John McCooke
Non-Executive Director
-
Mr. Bruce Edward Heath Hiscock
Executive Director, Chief Financial Officer
-
Mr. Peter John Harrison
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Liontrust Investment Partners LLP555,938
CFP SDL UK Buffettology Fund498,000
Liontrust UK Smaller Companies Fund478,827
WS Gresham House UK Multi Cap Income Fd421,126
Santander Asset Management UK Limited217,807

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
28 Apr 2025Purchase
16 Apr 2025Exercise of Option
23 Dec 2024Purchase
22 Nov 2024D
30 Oct 2024Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.